TAMPA, Fla., Sept. 5, 2025 ~ Tampa General Hospital and the TGH Cancer Institute have recently been awarded accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT), solidifying their position as leaders in cancer care in the region. This prestigious recognition is a testament to the academic health system's dedication to providing exceptional clinical care, promoting innovation, and prioritizing patient safety in stem cell transplant and cellular therapy.

FACT is a nonprofit organization that sets standards for high-quality medical and laboratory practices in cellular therapies, specifically the transplantation of living cells into the body. The accreditation process ensures that a program meets internationally recognized standards and utilizes best practices in patient care, cell collection, processing, and administration. This recognition is highly regarded by regulatory bodies such as the U.S. Food & Drug Administration, the Association for the Advancement of Blood & Biotherapies, The Joint Commission, and international societies.

Dr. Eduardo Sotomayor, vice president and executive director of the TGH Cancer Institute, expressed his gratitude for this recognition stating, "Tampa General is honored to be recognized by FACT. As a leading academic health system, we are constantly striving to provide our patients with innovative treatments. This accreditation serves as validation of our efforts as we continue to develop our Cancer Institute into a world-class resource for cancer patients."

More on Marylandian

• Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
• Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy
• Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
• Verbica Challenges Panetta to a Televised Debate on the Issues
• Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss

The TGH Cancer Institute's cellular therapy program offers cutting-edge treatments such as Chimeric Antigen Receptor (CAR) T-cell therapy and stem cell transplants for patients with aggressive blood cancers like lymphomas, multiple myeloma, and leukemias. Dr. Ivan Borrello leads this program as medical director of Myeloma, Bone Marrow Transplant (BMT), and Cell Therapies within the TGH Cancer Institute. He joined Tampa General in 2022 from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore.

Dr. Borrello shared his excitement about this achievement saying, "As we work towards developing options for patients with complex cancers, we have been focused on offering novel immune-based therapies to elevate our Bone Marrow Transplant and Cell Therapies Unit into a nationally and internationally recognized program. It is truly an honor to be recognized by FACT for our dedication and efforts to achieve excellence in our health system."

The TGH Cancer Institute's team of dedicated cell therapy nurses, practitioners, and social workers provide comprehensive care for patients in both inpatient and outpatient settings. This milestone not only highlights TGH's leadership in cellular therapy but also assures patients that they are receiving exceptional care from a team of experts who prioritize precision and compassion.

More on Marylandian

• K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
• Connecta Satellite Solutions Ready to Support Emergency Communications Following the Venezuela Earthquake
• Rare 1933 Harold Weston painting will be auctioned to benefit the Keene Valley Library
• $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
• HomeCentris Home Health Achieves 5-Star CMS Rating

Dr. Abraham Schwarzberg, executive vice president, chief of Oncology, president of the Tampa General Provider Network (TGPN), and co-vice president of Clinical and Translational Research at the TGH-USF Health Office of Clinical Research, emphasized the significance of this accreditation stating, "This recognition not only affirms TGH's leadership in cellular therapy but also offers patients the assurance that their care is delivered with exceptional expertise, precision, and compassion."

As one of the few Florida cancer centers backed by academic medicine through its partnership with the USF Health Morsani College of Medicine, the TGH Cancer Institute ranks among the top 10% of U.S. hospitals according to U.S. News & World Report's Best Hospitals 2025-2026. The Cancer Institute provides comprehensive care through groundbreaking therapies, advanced diagnostic imaging tools, and a highly coordinated interdisciplinary approach to patient care. It is also certified by the American College of Surgeons Commission on Cancer Accreditation and by the American Society of Clinical Oncology (ASCO) for meeting strict standards required by the society's Quality Oncology Practice Initiative (QOPI) program. Additionally, it has been named among America's Best Cancer Hospitals by Newsweek.

For more information about the TGH Cancer Institute and its services, please visit www.tgh.org/cancer.

---

Show All News | Disclaimer | Report Violation